Opinion

Video

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

Author(s):

Catherine C. Coombs, MD,Matthew S. Davids, MD, MMSc

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: BTKi degraders
Related Videos
Elizabeth Buchbinder, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
John M. Burke, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Related Content
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Mantle Cell Lymphoma | stock.adobe.com
December 17th 2024

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine
December 10th 2024

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8

Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute
December 12th 2024

Study Finds Quality of Life Maintained With Active Monitoring for DCIS